公司资料
Capricor Therapeutics 股价、新闻与催化剂
- 股票代码:
- CAPR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.45 USD (+12.03%)
收盘价
最后更新: 2026年8月17日
1.58B USD
市值
股价为何变动
As of Aug 17, 2026, CAPR closed up 12.0% at $7.45. No new same-company headline was identified in the current news window.
公司概览
Cell Therapy for Duchenne Muscular Dystrophy
Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.
Deramiocel
The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling.
HOPE-3 Evidence
The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
未来催化剂
- FDA decision on the deramiocel BLA for Duchenne muscular dystrophy.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。